丹麦前列腺癌患者诊断后他汀类药物使用与死亡率的关系
基于丹麦全国登记数据,纳入1998至2011年确诊的前列腺腺癌患者31790例,评估诊断后他汀使用(≥2次处方,1年滞后)与截至2013年的前列腺癌特异死亡和全因死亡的关系。诊断后他汀使用与前列腺癌死亡(调整HR 0.83,95%CI 0.77-0.89)和全因死亡(调整HR 0.81,95%CI 0.76-0.85)降低相关,但因果关系尚待确立。
要点
- 诊断后他汀使用与前列腺癌死亡风险降低相关(调整HR 0.83,95%CI 0.77-0.89)。
- 诊断后他汀使用与全因死亡风险降低相关(调整HR 0.81,95%CI 0.76-0.85)。
- 1年和5年暴露期敏感性分析结果相似,因果关系尚待确立。
核心结论
- 诊断后他汀使用与前列腺癌死亡和全因死亡降低相关,但该关联是否为因果尚待确立。
研究设计与样本
- 基于丹麦全国登记数据的队列研究,纳入1998至2011年确诊的前列腺腺癌患者31790例,诊断后他汀使用定义为≥2次处方并以1年滞后作为时变协变量,采用Cox比例风险回归模型计算截至2013年的风险比。
主要发现
- 中位随访2.8年(四分位距1.3至5.1年,自诊断后1年起算),31790例患者中7365例死于前列腺癌、11811例死于其他原因。
- 诊断后他汀使用与前列腺癌死亡的调整HR为0.83(95%CI 0.77至0.89),与全因死亡的调整HR为0.81(95%CI 0.76至0.85)。
- 1年和5年暴露期敏感性分析观察到相似结果。
- 按估计剂量、他汀类型、临床分期、Gleason评分或诊断前他汀使用分层,未发现实质性的效应修饰。
- 研究早期确诊或接受根治性前列腺切除术或内分泌治疗的患者,诊断后他汀使用与前列腺癌死亡的HR略低于总体分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出该关联是否为因果尚待确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Increasing evidence indicates that statin use may reduce mortality from prostate cancer. In this work, we examined whether postdiagnosis statin use was associated with reduced cancer-specific mortality or all-cause mortality among patients with prostate cancer in Denmark. Material and Methods From nationwide Danish registries, we identified all patients with incident prostate adenocarcinoma from 1998 to 2011 and retrieved data on tumor and patient characteristics, drug use, and primary treatment. We defined postdiagnosis use (two or more prescriptions) of statins as a time-varying covariate with 1-year lag. Cox proportional hazards regression models used to compute hazard ratios (HRs) for prostate cancer-specific mortality and all-cause mortality through 2013 associated with postdiagnosis statin use. In secondary and sensitivity analyses, we assessed statin use within exposure periods of 1 year or 5 years after prostate cancer diagnosis and evaluated the influence of prediagnosis statin use. Results Among 31,790 patients, 7,365 died of prostate cancer and 11,811 died from other causes during a median follow-up of 2.8 years (interquartile range, 1.3 to 5.1 years) from 1 year after diagnosis. Postdiagnosis statin use was associated with adjusted HRs of 0.83 (95% CI, 0.77 to 0.89) for prostate cancer mortality and 0.81 (95% CI, 0.76 to 0.85) for all-cause mortality. Similar results were observed in 1-year and 5-year sensitivity analyses. No substantial effect measure modification was found with estimated dose or type of statin, clinical stage, Gleason score, or with prediagnosis statin use; however, patients who were diagnosed early in the study period or who underwent radical prostatectomy or endocrine therapy exhibited slightly lower HRs for prostate cancer mortality with postdiagnosis statin use than did those in the overall analyses. Conclusion Postdiagnosis statin use was associated with reduced mortality from prostate cancer; however, it remains to be established whether this association is causal.
引用
- Larsen SB, Dehlendorff C, Skriver C, et al. Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer. J Clin Oncol. 2017. PMID: 28806117. doi:10.1200/JCO.2016.71.8981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。